OR14-002 - ANTI IL-1 therapies and pregnancy outcome by unknown
MEETING ABSTRACT Open Access
OR14-002 - ANTI IL-1 therapies and pregnancy
outcome
HJ Lachmann1*, H Ozdogan2, A Simon3, N Stewart1, DM Rowczenio1, S Ugurlu2, T Lane1, PN Hawkins1
From 7th Congress of International Society of Systemic Auto-Inflammatory Diseases (ISSAID)
Lausanne, Switerland. 22-26 May 2013
Introduction
Young women with autoinflammatory diseases on long
term IL-1 blockade are increasingly asking about the feasi-
bility, safety and outcomes of pregnancy but few data are
available. The FDA classes anakinra as pregnancy risk
grade B and rilonacept and canakinumab as grade C. The
manufacturers advise that there are no data on the out-
come of pregnancy or on excretion into breast milk and
that anakinra and canakinumab should only be taken if
the benefits outweigh risk; for rilonacept the advice is to
avoid in pregnancy. The literature contains only 3
reported cases of use of anakinra in pregnancy – all in
adult onset Stills disease (AOSD) and with successful
outcomes.
Objectives
To assess pregnancy outcomes in women who had
received anti IL-1 therapies in pregnancy.
Methods
We indentified women who have been exposed to anti
IL-1 agents in completed or planned to complete pregnan-
cies under our care. Data were collected on medication,
pregnancy outcome, breast feeding and development.
Results
7 cases were identified; 5 completed, 1 first and 1 second
trimester pregnancies. The underlying diseases were:
3 CAPS, 1 TRAPS, 1 FMF, 1 idiopathic pericarditis and
1 AOSD. 3 completed pregnancies (CAPS, TRAPS, peri-
carditis) were on anakinra from preconception throughout
the pregnancy, the 2 current pregnancies (CAPS) were on
canakinumab pre conception, 1 switched to anakinra
8 weeks pre conception, the other stopped canakinumab
8 weeks after conception and currently (12 weeks later) is
on no treatment. The patient with FMF also had multiple
sclerosis with presumed prolonged febrile myalgia refrac-
tory to colchicine for which she received 12 weeks of ana-
kinra from 22 weeks. The AOSD patient received anakinra
and prednisolone from 22 to 33 weeks. Median maternal
age was 30 years (25-38), all were first pregnancies. The 5
completed pregnancies resulted in 5 healthy boys; median
gestation 38 weeks (35 to 41). One baby was delivered by
caesarean section at 36 weeks for vaginal bleeding (FMF),
the others were vaginal deliveries (2 induced); median
birth weight 2.59 kg (2.02-3.94), 1 minute APGAR score
was 8 in 1 case and 9 in the rest. All were normal on
neonatal checks, one had evidence of unilateral reduced
hearing at 6 weeks. One was breast fed, the others bottle
fed. Follow up data is available on 3 beyond 6 months and
their development remains normal.
Conclusion
These 5 successful pregnancies more than double the
number of known outcomes in anakinra treated mothers
and provide reassurance to physicians caring for young
women. Nonetheless the numbers remain very small and
each pregnancy should be assessed and the risks and bene-
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